PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-95.21%
Revenue decline while GNPX shows 0.00% growth. Joel Greenblatt would examine competitive position erosion.
31.39%
Cost increase while GNPX reduces costs. John Neff would investigate competitive disadvantage.
-116.81%
Gross profit decline while GNPX shows 2.78% growth. Joel Greenblatt would examine competitive position.
-451.18%
Margin decline while GNPX shows 0.00% expansion. Joel Greenblatt would examine competitive position.
6.71%
R&D growth less than half of GNPX's 57.29%. David Dodd would verify if efficiency advantage is sustainable.
86.34%
G&A growth while GNPX reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
29.34%
Operating expenses growth above 1.5x GNPX's 0.82%. Michael Burry would check for inefficiency.
29.34%
Total costs growth above 1.5x GNPX's 0.82%. Michael Burry would check for inefficiency.
-100.00%
Both companies reducing interest expense. Martin Whitman would check industry trends.
31.39%
D&A growth while GNPX reduces D&A. John Neff would investigate differences.
-52.58%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
-3087.14%
EBITDA margin decline while GNPX shows 0.00% growth. Joel Greenblatt would examine position.
-52.01%
Both companies show declining income. Martin Whitman would check industry conditions.
-3075.40%
Operating margin decline while GNPX shows 0.00% growth. Joel Greenblatt would examine position.
137.14%
Other expenses growth 1.25-1.5x GNPX's 101.39%. Martin Whitman would scrutinize cost items.
-51.43%
Both companies show declining income. Martin Whitman would check industry conditions.
-3063.27%
Pre-tax margin decline while GNPX shows 0.00% growth. Joel Greenblatt would examine position.
100.00%
Similar tax expense growth to GNPX's 100.11%. Walter Schloss would investigate patterns.
-52.47%
Both companies show declining income. Martin Whitman would check industry conditions.
-3085.00%
Net margin decline while GNPX shows 0.00% growth. Joel Greenblatt would examine position.
-43.48%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-43.48%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
7.17%
Share count reduction below 50% of GNPX's 0.08%. Michael Burry would check for concerns.
7.17%
Diluted share reduction below 50% of GNPX's 0.03%. Michael Burry would check for concerns.